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To the Editor: We read with interest the recent article by
Serra et al.1 detailing a variety of glomerular lesions
(increased mesangial matrix, mesangial cell proliferation,
podocyte hypertrophy, and glomerulomegaly) in extremely
obese patients without clinical signs of renal dysfunction.
Despite using a broad array of clinical and biochemical
variables in their regression models, only body mass index
was found to be a significant predictor of glomerular lesions
in multivariate analysis.
We believe that serum aldosterone, if included in the
analysis, would have likely emerged as another important
predictor of obesity-related renal damage. Obesity is
frequently associated with elevated levels of aldosterone.2 In
the obese state, oxidized fatty acids likely stimulate
aldosteronogenesis;3 in vitro, human adipocytes secrete
potent mineralocorticoid-releasing factors.4 Aldosterone is
important in salt and water balance by acting on epithelial
mineralocorticoid receptors, but its effects through miner-
alocorticoid receptors in nonepithelial tissues may be more
important in the pathogenesis of chronic kidney disease. In
animal models, unopposed aldosterone in the presence of
high salt intake causes thrombotic and proliferative lesions in
the glomeruli and renal vessels.5–7 These pathologic lesions
occur independent of blood pressure, reflecting a direct,
nonepithelial, profibrotic effect of aldosterone on the kidney.
The increased glomerulosclerosis in these hyperaldoster-
one models typically result in severe proteinuria, a distinctly
different phenotype from Serra et al.’s extremely obese
subjects whose clinical renal function was normal. The
authors, however, argue that the early lesions found in this
study are potential harbingers of future, overt kidney disease.
If so, then the glomerular lesions described in this study will
likely progress to the more sclerotic lesions typified in the
seminal animal studies discussed above.
The role of aldosterone in obesity-related kidney injury
becomes more important as the discussion shifts toward
potential treatment options. Serra et al. admit that their study
does not address whether bariatric surgery could reverse the
renal lesions seen on biopsy, and the authors cite a study in
which angiotensin-converting enzyme inhibitors and statins
ameliorate podocyte damage in obese rats.8 In dogs fed a
high-fat diet, the use of an aldosterone antagonist (compared
to untreated controls) markedly attenuated obesity-induced
glomerular hyperfiltration, sodium retention, and hyperten-
sion.9 Because it will not be possible to offer all extremely
obese patients bariatric surgery, it may be beneficial to check
these patients’ aldosterone levels and, if elevated, prescribe
mineralocorticoid receptor blockers and salt restriction for
renal protection. Alternatively, empiric treatment with
mineralocorticoid receptor blockers and a low-salt diet may
be undertaken even without aldosterone measurement,
recognizing the possibility that mineralocorticoid receptor
activation may also occur by elevated cortisol concentrations
in obesity.10
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We appreciate the comments of Dr Bomback and Dr
Klemmer on the possible relationship between aldosterone
and obesity-related renal lesions.1
Obesity is associated with elevated levels of several
hormones including aldosterone, leptin, adiponectin,
cortisol, renin, and angiotensin.2,3 Some of these
hormones, such as leptin, have been associated with
the production of renal lesions in animal models.4
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Experimental evidence suggests that aldosterone could be
responsible for thrombotic and proliferative lesions in the
glomeruli and renal vessels.5 On the other hand, the
administration of either spironolactone or angiotensin-
converting enzyme inhibitors reduced renal damage in a
rat model.6 Moreover, the administration of aldosterone
reversed the renal protection provided by blockade of the
renin–angiotensin–aldosterone system in another model.7
Therefore, significant experimental evidence exists that
aldosterone could produce renal injury. Likewise, there is
preliminary evidence stemming from the systematic review
by Bomback et al.8 that the combination of aldosterone
blockers and angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers could be useful in the
control of patients with proteinuric chronic kidney disease.
However, to our knowledge, no clinical studies have been
conducted relating aldosterone to the renal lesions found
in extremely obese (EO) patients. Such studies in obese
and non-obese subjects would be highly welcome because,
if they confirmed this relationship, the possibility of
potential treatment options would be opened up.
The lack of these clinical-pathologic studies is probably
due to the difficulty in obtaining renal tissue in the general
population for ethical reasons. Nevertheless, it is possible
to obtain renal tissue from EO patients during bariatric
surgery. Obesity and extreme obesity are health problems
of epidemic proportions and their prevention and treat-
ment are extremely important. Some of these EO patients
have microalbuminuria9 and could develop proteinuria
and chronic kidney disease in the course of the disease. The
great challenge is to discover new treatments to avoid
obesity and/or once established, prevent the mechanisms
of renal or other organ lesions induced by obesity and
related diseases such as arterial hypertension. Meanwhile,
we agree that the empiric use of aldosterone blockers and
low-salt diet or the use of angiotensin-converting enzyme
inhibitors10 and/or angiotensin receptor blockers in EO
patients in whom bariatric surgery is delayed or not
possible, could be an alternative treatment option.
In our article,9 we focused mainly on the description,
for the first time, of the glomerular architecture in renal
biopsies of EO patients with normal renal function. We did
not attempt to study pathogenic or treatment aspects in
depth. We centered exclusively on clinical-pathologic
correlations and demonstrated that body mass index is
an independent risk factor for glomerular lesions. Previous
clinical-epidemiologic data had suggested the existence of a
relationship between obesity and chronic kidney disease.11
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